Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: June 16, 2023
Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.
Journal: Cancer immunology research
Published: May 05, 2022
AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors.
AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 23, 2022
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Journal: Gynecologic oncology
Published: April 01, 2020
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2019
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 28, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 05, 2018
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 09, 2018
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 14, 2018
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 28, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 06, 2018
Last Updated: 09/26/2026